Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | F7 | P08709 | 12/20 | 0.44 |
| ▸ | F3 | P13726 | 2/20 | 0.44 |
| ▸ | MEN1 | O00255 | 2/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.43 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.43 |
| ▸ | LMNA | P02545 | 3/20 | 0.42 |
| ▸ | MAPT | P10636 | 2/20 | 0.42 |
| ▸ | HTT | P42858 | 1/20 | 0.42 |
| ▸ | GAA | P10253 | 2/20 | 0.41 |
| ▸ | PKM | P14618 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6794526 | 1.00 | F7 (0.44) | F7F3MEN1KMT2AL3MBTL1 | |
| SCHEMBL8363690 | 0.90 | MEN1 (0.42) | F7F3MEN1KMT2AL3MBTL1 | |
| SCHEMBL8363213 | 0.86 | F7 (0.57) | F7F3MEN1KMT2A | |
| SCHEMBL6791732 | 0.86 | F7 (0.48) | F7F3 | |
| SCHEMBL6791726 | 0.86 | F7 (0.48) | F7F3 | |
| SCHEMBL8360867 | 0.85 | F7 (0.42) | F7F3MEN1KMT2AL3MBTL1 | |
| SCHEMBL8360872 | 0.85 | F7 (0.43) | F7F3LMNAMAPTGAA | |
| SCHEMBL8360874 | 0.85 | F7 (0.42) | F7F3MAPTGAA | |
| SCHEMBL6791505 | 0.84 | F7 (0.52) | F7F3MEN1KMT2AL3MBTL1 | |
| SCHEMBL6794167 | 0.84 | F7 (0.52) | F7F3MEN1KMT2AL3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040082585-A1 | Prodrugs of substituted polycyclic compounds useful for selective inhibition of the coagulation cascade | PHARMACIA CORPORATION | 2004-04-29 | — | — | US | disclosed |
| WO-2003028729-A2 | PRODRUGS OF SUBSTITUTED POLYCYCLIC COMPOUNDS USEFUL FOR SELECTIVE INHIBITION OF THE COAGULATION CASCADE | PHARMACIA CORPORATION (US) | 2003-04-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040082585-A1 | Prodrugs of substituted polycyclic compounds useful for selective inhibition of the coagulation cascade | TFPI, F2, PLG | F7 54/4885F3 20/4885MEN1 1172/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.